Effects of long term nCPAP treatment on patients with obstructive sleep apnoea syndrom Source: Eur Respir J 2007; 30: Suppl. 51, 322s Year: 2007
Presence of sleep apnea syndrome in the group of severe and very severe COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 198s Year: 2006
Effects of CPAP treatment on physical fitness in patients with obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 97s Year: 2003
Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP Source: Sleep and Breathing Conference 2021 Year: 2021
Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP Source: Sleep and Breathing Conference 2021 Year: 2021
Does persistent daytime hypersomnolence in CPAP treated patients with OSAS reflect comorbid narcolepsy or restless legs syndrome ? Source: Annual Congress 2010 - Sleep disorders: neurology, smoking and daytime sleepiness Year: 2010
Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP. Source: Virtual Congress 2021 – Different treatment modalities and impact of comorbidities on sleep disordered breathing Year: 2021
Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP. Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing Year: 2021
Vasoconstriction during the night in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 419s Year: 2006
Effects of nCPAP treatment on quality of life of patients with obstructive sleep apnoea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 410s Year: 2006
Fibrinogen level in patients with severe obstructive sleep apnoea syndrome (OSAS). Effect of n-CPAP therapy Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
CPAP variability in long term follow-up of OSAS (obstructive sleep apnea syndrome) patients Source: Eur Respir J 2006; 28: Suppl. 50, 412s Year: 2006
The prevalence of unrecognized obstructive sleep apnea syndrome among patients with nocturnal symptoms and poorly controlled asthma Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017
PAI-uPA system in patients with obstructive sleep apnea syndrome (OSAS) in CPAP treatment Source: Annual Congress 2012 - Cardiovascular disease and sleep-disordered breathing Year: 2012
Effect of multiple-dose treatment with daridorexant on nighttime respiratory function in patients with mild and moderate obstructive sleep apnea (OSA) Source: Virtual Congress 2020 – Treatment of obstructive sleep apnoea and its effects Year: 2020
Compliance with CPAP/BiPAP treatment in obstructive sleep apnea syndrome patients Source: Annual Congress 2010 - Clinical aspects of sleep apnoea Year: 2010
Possibility of treating patients with obstructive sleep apnea syndrome and nocturnal asystoles using CPAP therapy Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009
The frequency of overlap syndrome in patients who were evaluated in sleep laboratory and its effects on severity of obstructive sleep apnea syndrome and quality of sleep Source: Annual Congress 2012 - Physiology, heart failure and respiration in relation to OSA Year: 2012
Treatment control in risk patients with obstructive sleep apnea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 411s Year: 2006
The use of systemic corticosteroids in children with obstructive sleep apnea syndrome Source: International Congress 2019 – Evaluation of breathing in children when they are asleep, healthy or ill Year: 2019